大麻素受体作为HTLV-1相关骨髓病变 (HAM/TSP) 治疗的新点

Afsane Fadaee1, Fatemeh Sadat Mohammadi2, Nazila Ariaee2

  • 1Faculty of Medicine, Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Azadi-Square, Medical Campus, Mashhad 9177948564, Iran; HTLV-1 Foundation, Ghaem Hospital, Mashhad University of Medical Sciences, Ahmad Abad Bolv., Mashhad, Iran.

概括

大麻素受体 (CBR) 在HTLV-1相关骨髓病变 (HAM/TSP) 中发生变化. 无症状载体中较高的CB1R和CB2R表达表明具有保护作用,可能有利于HAM/TSP患者接受大麻素治疗.